Cingulate (CING) Consolidated Net Income (2021 - 2026)
Cingulate's (CING) quarterly Consolidated Net Income came in at -$6.0 million in Q4 2025, up 3.85% YoY from -$5.8 million in Q4 2024, and up 19.74% on a QoQ basis from -$7.5 million in Q3 2025.
Cingulate (CING) Consolidated Net Income (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Consolidated Net Income data on file, last reported at -$6.0 million in Q4 2025.
- Quarterly Consolidated Net Income rose 3.85% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$17.1 million (down 10.17% YoY) and the FY2025 annual result came in at -$22.1 million, down 38.28% from the prior year.
- Consolidated Net Income grew to -$6.0 million in Q4 2025, from -$7.5 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$1.3 million in Q1 2021 to a low of -$15.3 million in Q3 2021.
- A 5-year average of -$4.7 million and a median of -$3.9 million in 2024 frame the typical range for Consolidated Net Income.
- The widest YoY moves for Consolidated Net Income: up 79.19% in 2022, down 197.16% in 2022.
- Tracing CING's Consolidated Net Income over 5 years: stood at -$2.7 million in 2021, then sank by 63.82% to -$4.3 million in 2022, then tumbled by 50.73% to -$6.6 million in 2023, then grew by 4.32% to -$6.3 million in 2024, then grew by 3.85% to -$6.0 million in 2025.
- The last three Consolidated Net Income figures came in at -$6.0 million (Q4 2025), -$7.5 million (Q3 2025), and -$3.6 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | -4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.64 Mn |
| Dec 31, 2025 | -6.03 Mn |
| Sep 30, 2025 | -7.51 Mn |
| Mar 31, 2025 | -3.61 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Sep 30, 2024 | -3.89 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -2.38 Mn |
| Dec 31, 2023 | -6.55 Mn |
| Sep 30, 2023 | -5.65 Mn |
| Jun 30, 2023 | -5.23 Mn |
| Mar 31, 2023 | -3.78 Mn |
| Dec 31, 2022 | -4.35 Mn |
| Sep 30, 2022 | -3.18 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.96 Mn |
| Dec 31, 2021 | -2.65 Mn |
| Sep 30, 2021 | -15.29 Mn |
| Jun 30, 2021 | -1.43 Mn |
| Mar 31, 2021 | -1.33 Mn |